Subcutaneous Recombinant Interferon-β-1a (Rebif®)A Review of its Use in the Treatment of Relapsing Multiple Sclerosis

被引：0
作者：
Mark Sanford
Katherine A. Lyseng-Williamson
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Multiple Sclerosis; Alemtuzumab; Glatiramer Acetate; Fingolimod; Expand Disability Status Scale Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Subcutaneous recombinant interferon-β-1a (SC IFNβ-1a) [Rebif®] is indicated as monotherapy for the prevention of relapses and progression of physical disability in patients with relapsing multiple sclerosis (MS). This article reviews the efficacy and tolerability of SC IFNβ-1a in this indication, with further discussion of its pharmacological properties and pertinent pharmacoeconomic studies.
引用
收藏
页码：1865 / 1891
页数：26
相关论文
共 177 条
[1]  
Calabrese M(2010)Cortical lesions in multiple sclerosis Nature Rev Neurosci 6 438-44
[2]  
Filippi M(2010)New perspectives in the natural history of multiple sclerosis Neurology 74 2004-15
[3]  
Gallo P(2011)Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria Ann Neurol 69 292-302
[4]  
Tremlett H(2010)Multiple sclerosis: risk factors, prodromes and potential causal pathways Lancet Neurol 9 727-39
[5]  
Zhao Y(2008)Disease-modifying therapy in multiple sclerosis: update and clinical implications Neurology 71 S8-13
[6]  
Rieckmann P(2007)Subcutaneous interferon-beta-1a: new formulation CNS Drugs 21 871-6
[7]  
Polman CH(2009)Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Mult Scler 15 219-28
[8]  
Reingold SC(1998)Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis Biodrugs 10 471-94
[9]  
Banwell B(2005)Subcutaneous recombinant interferon-beta-1a (Rebif®): a review of its use in relapsing-remitting multiple sclerosis Drugs 65 1295-312
[10]  
Ramagopalan SV(2005)Mechanisms of action for treatments in multiple sclerosis: does a heterogeneous disease demand a multitargeted therapeutic approach Biodrugs 19 299-308
12345678910